title: Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia.
abstract: Recent reports have highlighted the role of cellular immunity in anti-tumor defenses. T lymphocytes are known to play important part in anti-cancer immunity. The number and function of T lymphocytes are altered in chronic leukemia patients. CD3(+)CD56(+) T lymphocytes have also been found to be abnormal in cancer patients. We therefore investigated changes in the number and cytotoxicity of CD3(+)CD56(+) T lymphocytes in the peripheral blood of acute leukemia (AL) patients (excluding acute promyelocytic leukemia), to improve our understanding of the role of this T lymphocyte subset. We analyzed CD3(+)CD56(+) T lymphocyte numbers and cytotoxicities in healthy controls, AL patients, and AL patients with complete remission. Lymphocyte counts were performed in peripheral blood and flow cytometry was used to determine cell numbers and cytotoxicities. The absolute number of CD3(+)CD56(+) T lymphocytes was increased in AL patients (including acute myeloid [AML] and acute lymphocytic leukemia [ALL]) compared with healthy controls (P<0.05), but their functioning was significantly reduced (P<0.05). The number of CD3(+)CD56(+) T lymphocytes in AML and ALL patients who achieved remission following chemotherapy was close to healthy controls (P>0.05), but their functioning was still significantly reduced (P<0.05). In addition, the number of CD3(+)CD56(+) T lymphocytes increased significantly in AML patients with increased peripheral blood white blood cell (WBC) counts, and in ALL patients without increased WBCs. These results suggest that cellular immunity may respond to AML and ALL, but that lymphocyte cytotoxicity remains impaired. Dysfunction of CD3(+)CD56(+) T lymphocytes in AML and ALL patients may contribute to the failure of the host immune response against leukemic blasts.
authors.affiliation: Department of Medicine; The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical College; Wenzhou, PR China.
authors.forename: Wenjian
authors.initials: W
authors.lastname: Guo
authors.forename: Chao
authors.initials: C
authors.lastname: Xing
authors.forename: Aishu
authors.initials: A
authors.lastname: Dong
authors.forename: Xiaoji
authors.initials: X
authors.lastname: Lin
authors.forename: Ying
authors.initials: Y
authors.lastname: Lin
authors.forename: Baoling
authors.initials: B
authors.lastname: Zhu
authors.forename: Muqing
authors.initials: M
authors.lastname: He
authors.forename: Rongxing
authors.initials: R
authors.lastname: Yao
mesh_terms: D017252:CD3 Complex / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D016022:Case-Control Studies; D003602:Cytotoxicity, Immunologic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000276:immunology*; D018655:Lymphocyte Count; D054353:Perforin / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism
chemical_list: D017252:CD3 Complex; D019002:CD56 Antigen; C522918:NCAM1 protein, human; D054353:Perforin
keywords: CD3+CD56+ T lymphocyte; cell’s cytotoxicity; cell’s number; primary acute leukemia
references.citation: Ann Hematol. 1997 Feb;74(2):51-6
references.pmid: 9063373
references.citation: Blood. 2009 Oct 29;114(18):3909-16
references.pmid: 19710498
references.citation: Cancer Immunol Immunother. 2002 Oct;51(8):440-8
references.pmid: 12202905
references.citation: J Clin Invest. 2005 Jul;115(7):1797-805
references.pmid: 15965501
references.citation: J Exp Med. 2005 Dec 19;202(12):1623-6
references.pmid: 16365145
references.citation: Nature. 2011 Dec 21;480(7378):480-9
references.pmid: 22193102
references.citation: Exp Hematol. 1997 Mar;25(3):246-51
references.pmid: 9091301
references.citation: Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5
references.pmid: 19332800
references.citation: J Clin Invest. 2008 Jul;118(7):2427-37
references.pmid: 18551193
references.citation: Leukemia. 2003 Oct;17(10):1973-80
references.pmid: 14513047
references.citation: Eur J Immunol. 2006 Jan;36(1):236-44
references.pmid: 16380959
references.citation: J Exp Med. 2004 Apr 5;199(7):947-57
references.pmid: 15051763
references.citation: Cell Mol Life Sci. 2001 Mar;58(3):442-69
references.pmid: 11315191
references.citation: Nat Immunol. 2000 Jul;1(1):23-9
references.pmid: 10881170
references.citation: Immunol Today. 2000 Nov;21(11):573-83
references.pmid: 11094262
references.citation: J Immunol. 1994 Aug 15;153(4):1687-96
references.pmid: 7519209
references.citation: Immunol Lett. 2004 Aug 15;95(1):5-11
references.pmid: 15325792
references.citation: Immunology. 2001 Jul;103(3):281-90
references.pmid: 11454057
references.citation: Ger Med Sci. 2007 Sep 10;5:Doc07
references.pmid: 19675715
references.citation: Blood. 1998 Nov 1;92(9):3318-27
references.pmid: 9787169
references.citation: J Immunol. 2000 Feb 1;164(3):1148-52
references.pmid: 10640724
references.citation: Blood. 1990 Feb 1;75(3):555-62
references.pmid: 2297567